ResMed (MEX:RMD) ROCE %: 27.24% (As of Mar. 2026)


MEX:RMD ResMed Inc MEX:RMD
99 GF Score
Price MXN3,716.10
GF Value MXN5,298.64
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is ResMed ROCE %?

ResMed MEX:RMD 99 ROCE % is 27.24% as of Mar. 2026. GuruFocus rates MEX:RMD with a GF Score™ of 99/100 and a GF Value™ of MXN5,298.64 (Significantly Undervalued). The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. ResMed's annualized ROCE % for the quarter that ended in Mar. 2026 was 27.24%.

ResMed  (MEX:RMD) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

ResMed ROCE % Related Terms

ResMed ROCE % Historical Data

* Premium members only.

The historical data trend for ResMed's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ResMed ROCE % Chart

ResMed Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21.63 24.02 20.64 23.93 26.05

ResMed Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.16 25.44 25.69 27.57 27.24
MEX:RMD
99GF Score
ResMed Inc MEX:RMD
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ResMed ROCE % Calculation

ResMed's annualized ROCE % for the fiscal year that ended in Jun. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=31772.279/( ( (125902.966 - 16683.293) + (153917.243 - 19189.214) )/ 2 )
=31772.279/( (109219.673+134728.029)/ 2 )
=31772.279/121973.851
=26.05 %

ResMed's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=36051.696/( ( (153109.129 - 22473.166) + (158404.376 - 24365.965) )/ 2 )
=36051.696/( ( 130635.963 + 134038.411 )/ 2 )
=36051.696/132337.187
=27.24 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 27.24% mean?
ResMed (MEX:RMD) has a ROCE % of 27.24% as of Mar. 2026.
Is ResMed's ROCE % too high?
ResMed's current ROCE % is 27.24%. The Medical Devices & Instruments industry median ROCE % is 2.23. ResMed's value of 27.24% is 1121.5% above this industry median. Overall, ResMed has a GF Score™ of 99/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ResMed's ROCE % compare to MDLN and WST?
ResMed's ROCE % of 27.24% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. ResMed's value of 27.24% is 1121.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ResMed's current ROCE % of 27.24% is 1121.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ResMed's current ROCE % is 27.24%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ResMed stock overvalued right now?
Based on GuruFocus' analysis, ResMed (MEX:RMD) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN5,298.64, compared to a current price of MXN3,716.10 — trading 29.9% below its estimated fair value. The current ROCE % is 27.24% and 1121.5% above the Medical Devices & Instruments industry median of 2.23. ResMed's overall GF Score™ is 99/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For ResMed (MEX:RMD), the current ROCE % is 27.24% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ResMed (MEX:RMD) Overvalued in 2026?

Based on GuruFocus' analysis, ResMed stock appears to be undervalued. The current stock price of MXN3,716.10 is trading 29.9% below its estimated GF Value™ of MXN5,298.64. GuruFocus considers ResMed to be Significantly Undervalued.

Key valuation signals for MEX:RMD:

  • ROCE %: 27.24%
  • GF Value™: MXN5,298.64 vs. price of MXN3,716.10 (29.9% below fair value)
  • GF Score™: 99/100 with 1 warning sign
  • Industry Position: 1121.5% above the Medical Devices & Instruments median

No single metric tells the full story. See the MEX:RMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ResMed Business Description

Address 9001 Spectrum Center Boulevard, San Diego, CA, USA, 92123
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
99GF Score

Get the complete analysis for MEX:RMD

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN3,716.10
Price
MXN5,298.64
GF Value